Your browser doesn't support javascript.
loading
Healthcare Cost Trajectories in the Last 2 Years of Life Among Patients With a Solid Metastatic Cancer: A Prospective Cohort Study.
Balasubramanian, Ishwarya; Finkelstein, Eric; Malhotra, Rahul; Ozdemir, Semra; Malhotra, Chetna.
Afiliação
  • Balasubramanian I; Lien Centre for Palliative Care.
  • Finkelstein E; Lien Centre for Palliative Care.
  • Malhotra R; Program in Health Services and Systems Research, and.
  • Ozdemir S; Program in Health Services and Systems Research, and.
  • Malhotra C; Centre for Ageing Research and Education, Duke-NUS Medical School, Singapore.
J Natl Compr Canc Netw ; 20(9): 997-1004.e3, 2022 09.
Article em En | MEDLINE | ID: mdl-36075386
ABSTRACT

BACKGROUND:

Most studies describe the "average healthcare cost trend" among patients with cancer. We aimed to delineate heterogeneous trajectories of healthcare cost during the last 2 years of life of patients with a metastatic cancer and to assess the associated sociodemographic and clinical characteristics and healthcare use. PATIENTS AND

METHODS:

We analyzed a sample of 353 deceased patients from a cohort of 600 with a solid metastatic cancer in Singapore, and we used group-based trajectory modeling to identify trajectories of total healthcare cost during the last 2 years of life.

RESULTS:

The average cost trend showed that mean monthly healthcare cost increased from SGD $3,997 during the last 2 years of life to SGD $7,516 during the last month of life (USD $1 = SGD $1.35). Group-based trajectory modeling identified 4 distinct trajectories (1) low and steadily decreasing cost (13%); (2) steeply increasing cost in the last year of life (14%); (3) high and steadily increasing cost (57%); and (4) steeply increasing cost before the last year of life (16%). Compared with the low and steadily decreasing cost trajectory, patients with private health insurance (ß [SE], 0.75 [0.37]; P=.04) and a greater preference for life extension (ß [SE], -0.14 [0.07]; P=.06) were more likely to follow the high and steadily increasing cost trajectory. Patients in the low and steadily decreasing cost trajectory were most likely to have used palliative care (62%) and to die in a hospice (27%), whereas those in the steeply increasing cost before the last year of life trajectory were least likely to have used palliative care (14%) and most likely to die in a hospital (75%).

CONCLUSIONS:

The study quantifies healthcare cost and shows the variability in healthcare cost trajectories during the last 2 years of life. Policymakers, clinicians, patients, and families can use this information to better anticipate, budget, and manage healthcare costs.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Segunda Neoplasia Primária / Neoplasias Tipo de estudo: Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Natl Compr Canc Netw Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Segunda Neoplasia Primária / Neoplasias Tipo de estudo: Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Natl Compr Canc Netw Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article